NCT06846554 - "A Trial of APL-9796'' in Adults With Pulmonary Hypertension" | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 9, 2025

Primary Completion Date

August 30, 2027

Study Completion Date

September 30, 2027

Conditions

Pulmonary Arterial Hypertension

Interventions

DRUG

APL-9796

3 Cohorts are planned in Part A.

DRUG

APL-9796

The decision to initiate optional Part B in WHO Group 3 PH-ILD participants will be made by the Safety Review Committee (SRC).

Trial Locations (1)

RECRUITING

Hammersmith/Imperial Hospital, London